Structure Therapeutics Inc.’s GPCR share price has dipped by 12.27%, which has investors questioning if this is right time to buy.

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer a competitive edge. Read more about GPCR stock here.

The cuticle is your hair’s protective outer layer, and when it’s healthy, it’s smooth and flat. Damage can lift some of the ...

Over time biomolecular condensates' redox activity drops and tangled aggregates linked to conditions like Alzheimer's ...

We took three of the cyclically hydrogen bonded polypeptide chains from the polyglycine II structure, built them and after rotating the chains to make a coiled coil, we found that the model came ...

Xencor, Inc., the US Court of Appeals for the Federal Circuit confirmed that the limiting preamble of a Jepson claim must be supported ...

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin resistance, β-cell dysfunction, and impaired ...

Haemolytic disease of the fetus and newborn (HDFN) occurs when there is transplacental passage of maternal immunoglobulin G ...